Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "equity"

432 News Found

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge
News | May 12, 2026

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market


Shareholders approve J.B. Pharma merger with Torrent Pharma
News | May 12, 2026

Shareholders approve J.B. Pharma merger with Torrent Pharma

Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held


Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
News | May 11, 2026

Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million

Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint


Experts push for patient-centric healthcare at IHW Patient First Summit 2026
Healthcare | May 11, 2026

Experts push for patient-centric healthcare at IHW Patient First Summit 2026

Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care


Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million
News | May 08, 2026

Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit


Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%
News | May 06, 2026

Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%

The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms


Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan
Biopharma | May 04, 2026

Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan

Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance


Thermo Fisher to sell microbiology business in $1.075 billion deal with Astorg
News | May 02, 2026

Thermo Fisher to sell microbiology business in $1.075 billion deal with Astorg

The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment


Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
interviews | May 01, 2026

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules